Novo Nordisk shifts marketing of GLP-1 drugs from obesity 'patients' to lifestyle 'customers'

Novo Nordisk is increasingly positioning its GLP-1 medications as lifestyle drugs for 'customers' rather than obesity medicines for 'patients,' marking a significant shift in how the company markets these treatments. The change comes as the company continues developing next-generation weight loss drugs and expands its product pipeline.